kt-5926 and Leukemia--Basophilic--Acute

kt-5926 has been researched along with Leukemia--Basophilic--Acute* in 1 studies

Other Studies

1 other study(ies) available for kt-5926 and Leukemia--Basophilic--Acute

ArticleYear
Inhibition of IgE-mediated histamine release by myosin light chain kinase inhibitors.
    Biochemical and biophysical research communications, 1992, Feb-28, Volume: 183, Issue:1

    Wortmannin, a specific inhibitor of myosin light chain kinase (MLCK) blocked IgE mediated histamine release from rat basophilic leukemia cell (RBL-2H3) and human basophils dose-dependently. Its IC50 was 20 nM for RBL-2H3 cells and 30 nM for human basophils. There was complete inhibition at the concentration of 1 microM. Wortmannin inhibited partially the A23187 induced histamine release from RBL-2H3 cells (40% inhibition at 1 microM). This inhibition was not accompanied by any significant effect on cytosolic free calcium concentration [( Ca2+]i). KT5926, another MLCK inhibitor, inhibited histamine release comparably with wortmannin and blocked to some degree the increase of [Ca2+]i in RBL-2H3 cells. Thus, the phosphorylation of myosin seems to be involved in signal transduction through Fc epsilon RI.

    Topics: Alkaloids; Androstadienes; Animals; Basophils; Calcimycin; Calcium; Carbazoles; Dose-Response Relationship, Drug; Histamine Release; Humans; Immunoglobulin E; Indoles; Leukemia, Basophilic, Acute; Myosin-Light-Chain Kinase; Rats; Tumor Cells, Cultured; Wortmannin

1992